Table 2.
Distribution of AMH values in the HBOC population, BRCA1 P/LPV carriers and BRCA2 P/LPV carriers compared with the expected nomogram for the general population
| Percentile Distribution in Study Population (HBOC) | Nomogram | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 0–5 | 5–50 | 50–95 | 95–100 | Total | 0–5 | 5–50 | 50–95 | 95–100 | p-value |
| 20–29 | 5 (18%) | 11 (39%) | 12 (43%) | 0 (0%) | 28 (100%) | 5% | 45% | 45% | 5% | 0.012 |
| 30–34 | 0 (0%) | 13 (57%) | 9 (39%) | 1 (4%) | 23 (100%) | 5% | 45% | 45% | 5% | 0.567 |
| ≥35 | 5 (14%) | 11 (31%) | 19 (54%) | 0 (0%) | 35 (100%) | 5% | 45% | 45% | 5% | 0.020 |
| Total | 10 (12%) | 35 (41%) | 40 (47%) | 1 (1%) | 86 (100%) | 5% | 45% | 45% | 5% | 0.019 |
| Percentile Distribution in BRCA1 P/LPV carriers | Nomogram | |||||||||
| 20–29 | 3 (27%) | 4 (36%) | 4 (36%) | 0 (0%) | 11 (100%) | 5% | 45% | 45% | 5% | 0.008 |
| 30–34 | 0 (0%) | 4 (44%) | 4 (44%) | 1 (11%) | 9 (100%) | 5% | 45% | 45% | 5% | 0.771 |
| ≥35 | 2 (17%) | 2 (17%) | 8 (67%) | 0 (0%) | 18 (100%) | 5% | 45% | 45% | 5% | 0.064 |
| Total | 5 (16%) | 10 (31%) | 16 (50%) | 1 (3%) | 32 (100%) | 5% | 45% | 45% | 5% | 0.030 |
| Percentile Distribution in BRCA2 P/LPV carriers | Nomogram | |||||||||
| 20–29 | 2 (13%) | 6 (38%) | 8 (50%) | 0 (0%) | 16 (100%) | 5% | 45% | 45% | 5% | 0.409 |
| 30–34 | 0 (0%) | 7 (70%) | 3 (30%) | 0 (0%) | 10 (100%) | 5% | 45% | 45% | 5% | 0.409 |
| ≥35 | 2 (10%) | 8 (40%) | 10 (50%) | 0 (0%) | 20 (100%) | 5% | 45% | 45% | 5% | 0.528 |
| Total | 4 (9%) | 21 (46%) | 21 (46%) | 0 (0%) | 46 (100%) | 5% | 45% | 45% | 5% | 0.312 |
HBOC hereditary breast and/or ovarian cancer, P/LPV pathogenic/likely pathogenic variants.